Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLNCF) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Silence Therapeutics (SLNCF) over the last 6 years, with Q3 2025 value amounting to $40.4 million.

  • Silence Therapeutics' Net Cash Flow rose 17309.18% to $40.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 11929.02%. This contributed to the annual value of $52.5 million for FY2024, which is 116348.37% up from last year.
  • According to the latest figures from Q3 2025, Silence Therapeutics' Net Cash Flow is $40.4 million, which was up 17309.18% from -$23.4 million recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Net Cash Flow ranged from a high of $74.9 million in Q1 2024 and a low of -$56.7 million during Q1 2025
  • Moreover, its 5-year median value for Net Cash Flow was -$4.3 million (2024), whereas its average is $2.6 million.
  • Data for Silence Therapeutics' Net Cash Flow shows a peak YoY increase of 1670649.72% (in 2022) and a maximum YoY decrease of 125310.96% (in 2022) over the last 5 years.
  • Over the past 5 years, Silence Therapeutics' Net Cash Flow (Quarter) stood at $3.0 million in 2021, then crashed by 1253.11% to -$34.9 million in 2022, then surged by 72.37% to -$9.6 million in 2023, then soared by 499.44% to $38.5 million in 2024, then grew by 4.78% to $40.4 million in 2025.
  • Its last three reported values are $40.4 million in Q3 2025, -$23.4 million for Q2 2025, and -$56.7 million during Q1 2025.